3SOF

I think she is headed back up, all it needs is a little positive medical news
The chart and indicators look to be stabilizing and looking like its ready to move
up.

Volume: 3,141,126
Avg Vol (3m): 2,750,780

Technicals
Close Above the 50-day EMA
Close Above the 13-day EMA
Percentage Gainer

Last Price Quote is:
0.65%above 13-day EMA
0.38%above 50-day EMA
RS Rating: 77 

Fundamentals
Key Data:
Market Cap (M): $354.97 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/08/2006
Last Analyst Rating: Mkt Outperform

My pick for the upcoming "5th Edition Stock Picking Contest"

Load your guns,pull the trigger, and let's rock and roll......

 

PRESS RELEASE
 

Company Contact:
   
Press Contact:

AVI BioPharma, Inc.
   
Waggener Edstrom Bioscience

Michael Hubbard ([email protected])
   
Andie Long ([email protected])

(503) 227-0554
   
(202) 326-0791
   

Investor Contacts:
Lippert/Heilshorn & Associates, Inc.

Jody Cain ([email protected])

Brandi Floberg ([email protected])

(310) 691-7100

 

For Immediate Release

 

AVI BIOPHARMA ANNOUNCES FIRST QUARTER FINANCIAL RESULTS

 

PORTLAND, Ore. (May 5, 2006) – AVI BioPharma, Inc. (Nasdaq: AVII) today reported financial results for the three months ended March 31, 2006.

 

For the first quarter of 2006, AVI reported a net loss of $9.1 million, or $0.18 per share, compared with a net loss of $5.5 million, or $0.13 per share, for the first quarter of 2005. Results for the first quarter of 2006 include stock-based compensation expenses of approximately $1.9 million, of which approximately $1.1 million was upon adoption of SFAS 123R and approximately $830,000 related to the acceleration of the vesting of certain stock options. Results for the first quarter of 2005 do not include SFAS 123R compensation expenses since the adoption occurred at the beginning of January 1, 2006. Revenues for the first quarter of 2006 were $66,000, compared with $45,000 for the first quarter of 2005, reflecting higher grant revenues.

 

Research and development (R&D) expenses were $6.8 million in the first quarter of 2006, compared with $4.1 million in the first quarter of 2005. This increase was due primarily to an additional $1.1 million in employee costs, including approximately $540,000 upon adoption of SFAS 123R and approximately $430,000 related to the acceleration of the vesting of certain stock options. The increase in R&D expense also reflects $500,000 in AVI common stock issued to Chiron Corporation as the first milestone payment due under a license agreement granting AVI a nonexclusive license to Chiron's patents and patent applications for the research, development and commercialization of antisense therapeutics against hepatitis C virus, and $400,000 in contracting costs for the production of GMP subunits, which are used by AVI to manufacture compounds for future clinical trials. The remaining R&D increase was due to higher clinical trial and consultant costs.

 

General and administrative (G&A) expenses were $2.8 million in the first quarter of 2006, compared with $1.4 million in the first quarter of 2005. This increase was due primarily to an additional $1.2 million in employee costs, including approximately $510,000 upon adoption of SFAS 123R and approximately $400,000 related to the acceleration of the vesting of certain stock options. The remaining increase in G&A was due to higher accounting and legal costs.

 

1


--------------------------------------------------------------------------------



 

AVI had cash, cash equivalents and short-term securities of $49.4 million as of March 31, 2006, an increase of $2.4 million from December 31, 2005. This increase was due primarily to the receipt of $5.0 million in net proceeds from a stock purchase agreement with Cook Group Inc. and $3.0 million from the exercise of warrants and options during the first quarter of 2006, offset by $5.3 million used in operations and approximately $290,000 used for purchases of property and equipment and patent-related costs.

 

In January 2006 AVI announced that the final version of the 2006 defense appropriations act had been approved, which included an allocation of $11.0 million to fund AVI's ongoing defense-related programs. AVI's NEUGENE ® technology is being used to develop therapeutic agents against Ebola, Marburg and dengue viruses, as well as to develop countermeasures for anthrax exposure and antidotes for ricin toxin. This additional funding for 2006 has not been received and has not been reflected in AVI's 2006 first quarter financial statements.

 

"We believe that our third-generation NEUGENE antisense technology has proven potential in many unmet and underserved medical needs, some of which represent large market opportunities. Based on our robust development pipeline, we have the strategic option to out-license development for certain indications, while using our internal resources to pursue the development of others," said Denis R. Burger, Ph.D., chief executive officer of AVI BioPharma. "Our decision to license the device-delivery of AVI-4126 targeting a single gene in the field of vascular disease to one of the pre-eminent vascular device companies in the world, Cook Group, represents our ability to execute on this strategy.

 

"The strategic importance of the agreement with Cook Group is several fold," he continued. "Cook has both the resources and the experience to run drug-development programs targeting vascular disease, which typically are large and expensive undertakings. Cook also has the sales and marketing resources for product commercialization. Further, with this agreement in place we are now able to more fully focus on other promising opportunities, including hepatitis C, influenza A and coronary bypass artery graphing, among other programs."

 

Product Pipeline Update

 

Technology Overview

 

AVI has developed proprietary third-generation NEUGENE antisense technology, which is characterized by a novel synthetic backbone. NEUGENE antisense compounds are designed to bind to specific disease-causing gene sequences to disable or inactivate the disease process. AVI believes that this chemistry allows NEUGENE antisense agents to be more stable, specific, efficacious and safer than second-generation antisense compounds in clinical development by others.

 

AVI's clinical development is focused in two disease categories: cardiovascular disease and infectious disease. In addition, AVI applies its technology to certain other clinical applications that it believes are particularly amenable to antisense drug development, namely, genetic disorders, inflammatory diseases and oncology.

 

In September 2005 the company announced a new application of its proprietary NEUGENE technology, called ESPRIT (Exon Skipping Pre-RNA Interference Technology). ESPRIT therapeutics allow for fine genetic surgery at the RNA processing level that enables the deletion of disease-causing genetic sequences or the skipping of functional sequences that are over-expressed or harmful in certain diseases. In February 2006 the company announced publication of an article in Nature Medicine indicating that AVI's ESPRIT technology

 

2


--------------------------------------------------------------------------------



 

may hold significant potential to bypass faulty dystrophin gene expression in patients with muscular dystrophy. The company is applying the ESPRIT therapeutic approach in genetic disorders, including a potential collaborative program in muscular dystrophy, as well as to diseases with an immunologic component, such as diabetes and multiple sclerosis.

 

Cardiovascular Disease Program

 

Resten-NG (AVI-4126) is a NEUGENE antisense drug for treating cardiovascular restenosis, the re-narrowing of a coronary artery following angioplasty. Resten-NG inhibits the expression of the c-myc gene, which plays a key role in the development of the pathology leading to restenosis. In a completed Phase II study, AVI demonstrated that Resten-NG prevented restenosis at the site of balloon angioplasty as measured by angiography and intravascular ultrasound at six months. In March 2006, AVI announced a development and commercialization agreement with Cook Group Inc., in which Cook licensed AVI-4126 for the down-regulation of c-myc gene expression in vascular diseases. This agreement covers device-delivery of Resten-NG as well as Resten-MP™, the microparticle formulation of AVI-4126, for treating cardiovascular restenosis. As part of this agreement, Cook has assumed control of the ongoing APPRAISAL Phase II clinical study, in which Resten-MP is being evaluated in the prevention of cardiovascular restenosis when delivered intravenously in conjunction with the placement of one or more bare-metal stents. In preclinical studies, Resten-MP was as effective as AVI-4126 delivered by catheters or stents in preventing cardiovascular restenosis.

 

AVI is focusing in house efforts on developing AVI-5126 for the treatment of coronary artery bypass grafting based on strong preclinical data. The company plans to enter Phase Ib/II development with this program during 2006.

 

Infectious Disease Program

 

AVI's infectious disease program is extensive, and encompasses research on more than 50 different viruses representing most viral families and involves collaborations with investigators worldwide. Results from these studies have enhanced AVI's ability to design effective agents for emerging as well as for engineered pathogens. AVI's antiviral research program has produced antisense drugs shown to be active in preclinical studies against a wide range of RNA viruses, including HCV, influenza A virus, West Nile virus (WNV), dengue virus, SARS coronavirus, Ebola virus and Marburg virus. AVI has confirmation through independent laboratories of NEUGENE antisense efficacy in preclinical experiments against multiple strains of influenza, including avian influenza strain H5N1, a potential worldwide public health threat.

 

AVI plans to focus its antiviral drug development program on infectious diseases that represent large market opportunities. The company announced in June 2005 the acceptance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the treatment of HCV using the company's NEUGENE compound AVI-4065. In September 2005 AVI announced the initiation of an HCV clinical trial to assess the safety, tolerability, pharmacokinetics and viral response to treatment with AVI-4065 in healthy volunteers and patients with chronic active HCV. The company reported favorable safety, tolerability and pharmacokinetic results in January 2006 from the first phase of its HCV program. AVI is currently in the second phase of the study involving patients with chronic HCV infection.

To address the large influenza commercial market, AVI has developed NEUGENE antisense drug candidates that target genetic regions of the influenza A virus that are highly conserved between the six viral subtypes that cause human disease. These include three subtypes that caused pandemics in the 20 th century – the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) – and three subtypes of avian flu that have been reported to cause disease in humans (H5N1, H7N7 and H9N2). Collaborators have

3

--------------------------------------------------------------------------------
confirmed that a single NEUGENE drug was effective in preclinical studies against most influenza subtypes, including the emerging H5N1 avian strain. AVI plans to file an IND later this year for its NEUGENE drug for avian flu that is also efficacious against the far more common influenza A viruses, which kill an average of 35,000 Americans every year.

The company is collaborating with the Centers for Disease Control and Prevention (CDC) in its dengue virus program, and expects dengue fever/dengue hemorrhagic fever to be the next viral program to move into clinical development.

Bio-Defense Program

AVI has an active collaborative program with the Department of Defense in the area of bio-threats and emerging diseases. In 2005 and early 2006, AVI received approximately $4.6 million for ongoing programs in drug development for the highly lethal Ebola and Marburg viruses, and countermeasures for ricin and anthrax toxins. In January 2006, the final version of the 2006 defense appropriations act was approved, which included an allocation of $11.0 million to fund AVI's ongoing defense-related programs.

 
Conference Call

 
AVI BioPharma has scheduled an investor conference call regarding this announcement, and its current and planned business activities, to be held today, beginning at 11:00 a.m. Eastern time.

 
Individuals interested in listening to the conference call may do so by dialing (888) 803-8271 within the U.S. and Canada, or (706) 634-2467 for international callers. A telephone replay of the conference call will be available for 48 hours beginning within two hours of the conclusion of the call, by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation number 1085185.

 
The live conference call also will be available to private investors via the Internet at www.avibio.com. A replay of the call will be available on the company's Web site for 14 days following the completion of the call.
 

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at www.www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

 

Up in the after hours to.....$6.80, I consider a strong buy.
I'm looking for this to be a gap up tomorrow, JMHO of course.
Close above the 13-day AND 50-day EMA.
MACD and Stochastic have bottomed , I'm looking for a run....

Technicals
Percentage Gainer

Last Price Quote is:
4.58%above 13-day EMA
1.42%above 50-day EMA
RS Rating: 7 

Fundamentals
Key Data:
Market Cap (M): $326.13 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2006
Last Analyst Rating: Mkt Outperform

Press Release Source: AVI BioPharma, Inc.


AVI BioPharma Reports Preclinical Data Against Multiple Strains of Influenza
Tuesday May 9, 9:00 am ET 
NEUGENE Antisense Efficacy Against Influenza Strains Reported at the International Conference on Antiviral Research


PORTLAND, Ore.--(BUSINESS WIRE)--May 9, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News), today presented positive preclinical data, resulting from preclinical experiments targeting multiple strains of influenza with NEUGENE® antisense compounds, at the 19th International Conference on Antiviral Research. The presentation, titled "Inhibition of Multiple Influenza A Subtypes with Antisense Phosphorodiamidate Morpholino Oligomers," detailed confirmatory studies by three independent laboratories, as reported previously, and presented new toxicology, pharmacokinetic and preliminary animal efficacy data.



Efficacy data observed in cell culture with the H1N1 strain, previously reported by Drs. Jianzhu and Chen Qin Ge at Massachusetts Institute of Technology, has been confirmed by Dr. P. Puthavathana at Mahidol University in Bangkok, Thailand, against an H5N1 viral isolate; by Dr. Darwyn Kobasa at the Public Health Agency of Canada in Winnipeg, Manitoba, against both the H1N1 and H3N2 strains; and by Dr. Manoj Pastey at Oregon State University in Corvallis, Ore., against the H7N7 and H3N8 strains.

These researchers have now completed toxicology and pharmacokinetic (PK) studies in rats, as well as preliminary efficacy studies in the first of several planned animal models. The toxicology and PK studies exhibited both a favorable safety profile and plasma clearance half-life, boding well for a possible future IND filing and clinical trial. In the initial animal studies using the fertilized egg model, low doses of a single NEUGENE antisense agent protected approximately half the animals from a lethal challenge with H1N1. Additional dose escalation studies with NEUGENE antisense agents are underway, and studies to evaluate protection of mice and ferrets against both H1N1 and H5N1 strains are planned to support an Investigational New Drug (IND) application.

"We believe that a single NEUGENE drug could be effective against most influenza subtypes," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "By targeting regions of the viral genetic code that are common to all influenza A subtypes, we expect that our NEUGENE drugs will be effective against avian flu and the far more common influenza A viruses, which kill an average of 35,000 Americans every year."

AVI's NEUGENE antisense drug development program against the influenza A virus targets genetic regions of the virus that are highly conserved across six viral subtypes that cause human disease. These include three subtypes that caused pandemics in the 20th century -- the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) -- and three subtypes of avian flu that have been reported to cause disease in humans (H5N1, H7N7 and H9N2).

AVI's Antiviral Program

AVI's proprietary NEUGENE antisense drug candidates have demonstrated efficacy in preclinical studies against SARS coronavirus, West Nile virus (WNV), hepatitis C virus (HCV), dengue virus, Ebola virus and Marburg virus. AVI has filed IND applications with the U.S. Food and Drug Administration and has ongoing clinical trials in WNV and HCV.

Showing how versatile NEUGENE drugs can be across viral subtypes, AVI demonstrated in its collaboration with the Centers for Disease Control and Prevention that NEUGENE agents are efficacious against all four immunologically distinct subtypes of the dengue virus. This outcome was achieved by targeting a highly conserved region of the dengue viral genetic code. In collaborative work with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) targeting the Ebola virus, NEUGENE drugs protected three animal species from lethal challenges with this virus (see PloS Pathog 2(1): e1). Additional clinical development efforts targeting dengue virus and Ebola virus are planned for 2006.

The speed with which effective NEUGENE drugs can be designed and manufactured exceeds any other modern drug development time frame. For example, NEUGENE compounds targeting SARS, WNV and Ebola were developed within days to weeks of obtaining the appropriate genetic sequences for the viruses.

AVI's Clinical Experience

AVI's NEUGENE antisense drugs have a well-defined safety record in human clinical trials. More than 300 patients have been dosed with NEUGENE drug candidates targeting host and viral gene targets in 12 clinical studies under multiple INDs. Five routes of administration have been employed in AVI's clinical studies, and doses up to 450 mg have been administered without a single drug-related serious adverse event. The combination of AVI's NEUGENE chemistry with conserved viral targets that are not expressed in the human genome makes a strong case for the potential for success in the development of candidates to address influenza, including the possible emergence of a transmittable avian flu.

About Influenza A Viruses

Influenza, or flu, is a contagious respiratory illness caused by influenza viruses. On average 5 percent to 20 percent of the U.S. population is infected with the flu each year. Influenza A virus is an enveloped negative-strand RNA virus, with eight genome segments that code for 10 proteins. Influenza strains are subtyped according to the antigenic and genetic nature of their surface glycoproteins: hemagglutinin (HA or H) and neuraminidase (NA or N). Fifteen H and nine N subtypes have been identified, with three associated with widespread human disease (H1N1, H2N2 and H3N2). In addition, several subtypes of avian influenza virus -- H5N1, H7N7 and H9N2 -- can infect and cause disease in humans.

The current influenza pandemic in birds throughout Asia, Eastern Europe and Turkey is caused by the H5N1 subtype. It is thought that co-infection of humans or certain animals (such as pigs) with both H1N1 and H5N1 can lead to a reassortment or recombination of viral particles, resulting in the emergence of a virus with dangerous public health properties, namely one to which the human population has no natural immunity and which has the ability to spread easily from person to person. It is believed that emergence of avian flu by this general mechanism may have led to the worldwide pandemics of 1918, 1957 and 1968.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.



Contact:
AVI BioPharma, Inc.
Michael Hubbard, 503-227-0554
[email protected]
or
Lippert/Heilshorn & Associates Inc.
Investor Contact
Jody Cain, 310-691-7100
[email protected]
or
Waggener Edstrom Worldwide Bioscience
and Healthcare Practice
Press Contact
Andie Long, 202-326-0791
[email protected]

--------------------------------------------------------------------------------
Source: AVI BioPharma, Inc.

AP
AVI BioPharma Data on Flu Drug Upheld
Tuesday May 9, 10:45 am ET 
AVI Biopharma Drug Data Stands Up to Peer Review, Company Moves Toward Application for Flu Drug


PORTLANE, Ore. (AP) -- AVI BioPharma Inc. on Tuesday said preclinical data showing its Neugene compounds are effective in targeting flu strains stood up to peer review in independent studies, moving AVI closer to filing an investigational new drug application.


Preclinical data comes from tests on animals, not humans. The investigational new drug application would clear the way for clinical trials of Neugene to treat various flu strains.

Data showing the compounds, which target specific genes, were effective in treating the H1N1 strain of influenza were confirmed as also being effective in three separate tests on other strains of the flu.

The strains H1N1, H2N2 and H3N2 are associated with the widespread human disease that infects millions each year. The strain that has spread in bird flocks from Southeast Asia through Turkey and into Europe is H5N1; other strains of avian flus include H7N7 and H9N2.

"We believe that a single Neugene drug could be effective against most influenza subtypes," said Patrick Iversen, AVI senior vice president of research and development.

Data from 300 patients who took AVI's Neugene drugs in clinical trials to treat other viruses showed the drug to be safe, with no instances of a serious adverse event.

AVI shares rose 16 cents, or 2.4 percent, to $6.88 in recent trading on the Nasdaq. In the past year, the stock has traded between $2.05 and $9.20.

Quote from: setravis on October 15, 2005, 02:11:17 PM
Huge potential super high flier for speculation. Ebola, Ricin, Avian flu drugs!
This stock could be a moon rocket based on speculation alone.

Here you go...AVII has more in it.....
after hours $7.35
Bird flu epidemic in US, movie is on ABC 8pm EST tonight.
I say after this AVII will be a big gainer tomorrow......   JMHO of course.
Tomorrow after people realize how serious this epidemic could and will be if Co's like AVII don't find a vaccine or antidote.

Volume: 5,465,436
Avg Vol (3m): 2,032,860

Technicals
Close Above the 50-day EMA
Close Above the 13-day EMA
Gap Up
Percentage Gainer

Last Price Quote is:
12.25%above 13-day EMA
9.51%above 50-day EMA
RS Rating: 9 

Fundamentals
Key Data:
Market Cap (M): $326.13 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2006
Last Analyst Rating: Mkt Outperform

Nice bounce off solid support on above average volume.  Let's see a close above the 200ma. 

Currently down 3% premarket.  Showing oversold on the daily chart with the 200ma "supporting" at 4.63.  Let's see if this bounce has any legs....

Approaching ascending trendline and support zone again.  Found support at $4.20 today and had some nice buying pressure this afternoon. 

Press Release Source: AVI BioPharma, Inc.


AVI BioPharma Added to NASDAQ Biotech Index
Tuesday May 23, 9:00 am ET


PORTLAND, Ore.--(BUSINESS WIRE)--May 23, 2006--AVI BioPharma, Inc. (Nasdaq: AVII - News), today announced that the company has been selected for inclusion in the NASDAQ Biotechnology Index (NASDAQ: NBI - News), as of Monday, May 22, 2006.


"Being included in the NASDAQ Biotechnology Index is a testament to our steady growth and achievements," said Alan P. Timmins, president and COO of AVI. "We will continue to execute on our goal to develop innovative infectious disease therapeutics and other antisense-based drugs intended to address unmet medical needs."

Launched in 1993, the NASDAQ Biotechnology Index includes companies that are listed on the NASDAQ national market and meet minimum requirements, including market value, average daily share volume and seasoning as a public company, among other criteria. The index is ranked on a semiannual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund. More information about the NASDAQ Biotechnology Index, including eligibility criteria, can be found at http://www.nasdaq.com.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE® antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at http://www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

Contact:
AVI Contact:
AVI BioPharma, Inc.
Michael Hubbard, 503-227-0554
[email protected]
or
Investor Contacts:
Lippert/Heilshorn & Associates Inc.
Jody Cain, 310-691-7100
[email protected]
or
Brandi Floberg, 310-691-7100
[email protected]
or
Press Contact:
Waggener Edstrom Worldwide
Bioscience and Healthcare Practice
Jenny Moede, 503-443-7507
[email protected]

--------------------------------------------------------------------------------
Source: AVI BioPharma, Inc.

bizjournals.com
AVI BioPharma on special Nasdaq index
Tuesday May 23, 1:37 pm ET


AVI BioPharma Inc. said Tuesday the company has been selected for inclusion in the Nasdaq Biotechnology Index, as of May 22.
Launched in 1993, the Nasdaq Biotechnology Index includes companies that are listed on the Nasdaq national market and meet minimum requirements, including market value, average daily share volume and seasoning as a public company, among other criteria. The index is ranked on a semiannual basis in May and November and serves as the basis for the iShares Nasdaq Biotechnology Index Fund.

Portland-based AVI BioPharma (NASDAQ: AVII - News) develops therapeutic products for the treatment of life-threatening diseases using antisense drugs.

Published May 23, 2006 by The Business Journal

Five bucks in the after hours, and rising! 

AVI BIOPHARMA INC (NasdaqNM:AVII) Delayed quote data 

After Hours (RT-ECN): $5.09... Up 0.47 (+10.17%)

Last Trade: 4.62
Trade Time: 4:00PM ET
Change:  0.01 (0.22%)
Prev Close: 4.61
Open: 4.66
Bid: 5.05 x 100
Ask: 5.06 x 1500
1y Target Est: 10.00

  Day's Range: 4.54 - 4.85
52wk Range: 2.05 - 9.20
Volume: 1,055,913
Avg Vol (3m): 2,311,210
Market Cap: 242.24M
P/E (ttm): N/A
EPS (ttm): -0.43
Div & Yield: N/A (N/A)

That looks like a bottom to me, as the sell off was over done.

Setravis, I agree looks like the bottom is in. I bought a little yesterday and will be buying more today. Applaud your updates.

AVI BioPharma Receives Notice of Allowance for a Patent Application Covering the Use of NeuGene Antisense Technology for the Development of a New Class of Antibiotics
Business Wire (Wed 9:00am) 

http://biz.yahoo.com/bw/060524/20060524005343.html?.v=1

AVI BIOPHARMA INC (NasdaqGM:AVII) Delayed quote data 

Pre-Market (RT-ECN): 3.70  0.18 (5.11%)